1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Soiken Holdings Inc.

Soiken Holdings Inc.

2385.T
Soiken Holdings Inc.JP flagTokyo Stock Exchange
210.00
JPY
-4.00
- -
5.49BMarket Cap
Soiken Holdings Inc.
2385.T
(Tokyo Stock Exchange)

Recent

price

210.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
55.56
58.27
59.36
75.3
89.57
97.44
122.83
158.57
208.54
289.32
356.01
341.86
357.36
308.89
197.2
185.35
197.2
Revenue per Share
-44.07
-10.92
-7.06
2.66
0.99
-0.21
1.79
7.13
7.57
21.16
27.97
21.49
30.95
17.27
-25.32
-8.05
-25.32
Basic EPS, GAAP
-26.58
-8.49
-8.47
3.04
-2.76
-3.67
6.31
3.89
-4.22
16.22
31.35
-5.03
79.95
-5.39
-34.23
19.9
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
0.97
1.99
3.92
5.02
4.97
4.98
5.03
0.01
- -
Dividend per Share
77.34
66.13
59.07
61.7
62.59
62.38
64.16
21.85
98.63
117.79
141.76
158.25
181.5
193.78
163.46
155.41
163.46
Book Value per Share
166.55
155.22
147.65
153.09
155.2
156.87
163.99
175.82
174.58
195
219.55
237.11
259.88
272.41
237.9
230.09
237.9
Tangible Book Value per Share
26
26
26
26
26
26
26
26
26
26
26
26
26
26
26
26
26
Basic Weighted Avg Shares
1,444
1,520
1,548
1,966
2,343
2,549
3,213
4,148
5,455
7,568
9,312
8,942
9,348
8,080
5,158
4,849
5,158
Sales/Revenue/Turnover
-46.19
-21
-12.14
2.92
1.19
-0.38
5.68
6.38
5.97
11.45
11.25
10.25
12.93
8.98
-11.83
-2.84
-11.83
Operating Margin (%)
569
22
21
18
18
16
16
21
32
34
35
31
24
25
27
18
- -
Depreciation Expense
-1,145
-285
-184
70
26
-6
47
187
198
553
732
562
810
452
-662
-211
-662
Net Income, GAAP
- -
- -
- -
31.31
44.89
203.34
55.95
31.34
38.04
34.53
31.58
36.07
34.76
37.18
- -
- -
16.29
Effective Tax Rate (%)
-79.31
-18.75
-11.89
3.54
1.11
-0.22
1.45
4.5
3.63
7.31
7.86
6.29
8.66
5.59
-12.84
-4.35
-12.84
Profit Margin (%)
3,369
3,109
2,924
2,994
3,018
3,472
3,643
3,912
3,834
4,309
5,426
6,000
6,572
6,920
6,085
5,841
6,085
Working Capital
- -
- -
- -
- -
- -
- -
- -
18
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
4,381
4,090
3,887
4,024
4,076
4,128
4,315
4,654
4,635
5,152
5,782
6,232
6,847
7,172
6,249
6,038
6,249
Total Equity
- -
- -
- -
0.99
0.38
0.24
1.88
3.93
4.23
11.33
12.55
9.42
11.73
6.35
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
4.75
1.94
-0.29
1.05
13.97
10.48
17.93
20.15
13.23
17.29
8.77
- -
- -
-5.14
Return on Capital (%)
-44.35
-15.26
-11.28
4.41
1.6
-0.34
2.82
16.58
12.56
19.55
21.55
14.32
18.22
9.21
-14.17
-5.05
-14.17
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'24
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
26
26
Market Capitalization
4,395
4,238
4,368

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'24
Jun'24
Total Current Assets
6,895
6,737
6,765
Cash, Cash Equivalents & STI
4,709
4,937
4,790
Accounts Receivable, Net
804
317
429
Inventories
1,093
1,148
1,121
Total Current Liabilities
685
623
680
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.15%
1.23%
-3.38%
Free Cash Flow
-244.42%
-306.97%
-158.13%
Net Income, GAAP
-76.71%
-67.61%
-68.18%
Sales/Revenue/Turnover
9.33%
-11.03%
-6.01%
Total Cash Common Dividend
- -
-14.36%
-99.84%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,125
1,716
1,001
1,317
5,158
2025
- -
- -
- -
- -
4,849
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-20.15
- -
- -
- -
-25.32
2025
- -
- -
- -
- -
-8.05
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
5.03
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
hVIVO plc (OPORF)
Halozyme Therapeutics, Inc. (HALO)
Q BioMed Inc. (QBIO)
Organicell Regenerative Medicine, Inc. (OCEL)
Century Therapeutics, Inc. (IPSC)
Ventyx Biosciences, Inc. (VTYX)
Business
Soiken Holdings Inc. Soiken Holdings Inc. (2385.T) is a Japan-based holding company primarily engaged in biomarker development and related bioventure activities originating from Osaka University. Founded in July 1994 and headquartered at 13F Senri Life Science Center in Toyonaka, Osaka, the company operates through six main business segments via its subsidiaries: biological evaluation systems including clinical evaluation tests for foodstuffs and biomarker licensing through Soiken Inc.; healthcare support services such as specific health guidance, health checkups, and diabetes prevention for health insurance societies; cosmetics manufacturing and sales focused on placenta extract products under the Placenta Laboratory brand through Bb Laboratories Inc.; dietary supplements featuring imidapeptides from anti-fatigue research projects through Japan Preventive Medicine Inc.; marketing research and post-marketing surveys for health supplements through Evidence Labo Inc.; and functional material development centered on lactoferrin and pharmaceutical compounds like ascochlorin derivatives through NRL Pharma Inc. The company primarily serves pharmaceutical, food, and healthcare sectors in Japan, with additional cosmetics outreach to the Chinese market via a capital alliance with Beautyplus Holdings Hong Kong Limited established in May 2015; its most recent notable ownership development occurred in 2021 when Hangzhou Golong Holding Co., Ltd. acquired a 10.7% stake for 1.1 billion yen, while it maintains ongoing biomarker commercialization efforts including gene therapy vectors through Virus Ikagaku Kenkyusho Inc.